Weight loss field expands as Pfizer's oral GLP-1 gathers comparisons to Novo's Wegovy in PhII data
Pfizer’s attempt to catch up in the weight loss market picked up steam on Monday with research showing the company’s GLP-1 agonist helped people with type 2 diabetes shed weight.
With data published in the JAMA network, led by Pfizer VP Aditi Saxena, the Big Pharma took a step closer to staking its spot in the burgeoning R&D field for obesity drugs, many of which started as diabetes meds, and are touted as becoming the biggest drug class in history with more than $100 billion on the line.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.